0.00Open1.02Pre Close0 Volume8 Open Interest380.00Strike Price0.00Turnover187.99%IV62.75%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry1.02Extrinsic Value100Contract SizeAmericanOptions Type0.0443Delta0.0015Gamma229.53Leverage Ratio-0.3690Theta0.0018Rho10.17Eff Leverage0.0307Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet